Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...

LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

PSMA PET scans significantly enhance detection and staging of prostate cancer, improving patient stratification and survival outcomes. Three FDA-approved PSMA PET scans are available, aiding in both ...

MILAN — When added to prostate biopsy, gallium-68 prostate-specific membrane antigen (PSMA)-PET/CT improves detection of clinically significant prostate tumors and helps guide treatment planning, new ...

PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.